Will Dr Lal PathLabs Sustain Growth Despite Expensive Valuations?
About Dr Lal PathLabs Q2FY26 Performance
Dr Lal PathLabs reported 11% YoY growth each in sales and EBITDA for Q2FY26, largely in line with Goldman Sachs estimates. Seasonal uptick lifted EBITDA margin to ~30.7%, while revenue momentum was driven by higher test volumes and network expansion efforts.
The company maintained its FY26 guidance of 11–12% revenue growth and 27–28% margins, with continued investment in infrastructure and front-end sales teams expected to keep costs elevated in H2. Goldman Sachs cut FY26–28E EPS by ~1% to reflect updated management commentary and notes that valuations at 29× FY27E EV/EBITDA appear expensive relative to ~11% EBITDA CAGR.
For precision tracking during market volatility, follow Nifty setups
Valuation & Investment View
- Short-term: Range-bound as margins normalize post seasonal boost.
- Medium-term: Network expansion may support stable earnings.
- Long-term: Rich valuations limit upside potential unless volume growth accelerates.
For sector-weight rotation insights, rely on Bank Nifty swing indicators compiled by our derivatives desk
Related Queries on Dr Lal PathLabs Valuation Outlook
- What drives Dr Lal PathLabs’ premium valuation multiple?
- How could expansion costs affect margin trajectory?
- Is volume growth sufficient to offset rising expenses?
SEBI Disclaimer: The information provided in this post is for informational purposes only and should not be construed as investment advice. Readers must perform their own due diligence and consult a registered investment advisor before making any investment decisions. The views expressed are general in nature and may not suit individual investment objectives or financial situations.
